ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia
Lymphoblastic Leukemia, Acute, Lymphoma, Non-Hodgkin
About this trial
This is an interventional treatment trial for Lymphoblastic Leukemia, Acute focused on measuring non-B ALL, relapse, treatment, Relapsed non-B ALL or non-B non-Hodgkin lymphoma
Eligibility Criteria
Inclusion Criteria: Up to 18 years of age Morphologically confirmed diagnosis of relapsed non-B ALL or non-B non-Hodgkin lymphoma Exclusion Criteria: They have completed the 18th year of life at the time the relapse is diagnosed. Curative therapy is declined either by patient himself/herself or the respective legal guardian The patient is pregnant The patient is breast feeding Essential parts of the relapse therapy are declined either by the patient or his/her legal cannot be administered because of medical reasons. No consent is given for transmission of data The patient has a severe concomitant disease that does not allow treatment according to protocol (e.g. malformation syndromes, cardiac malformations, metabolic disorders).
Sites / Locations
- ALL-REZ Studienzentrale
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
R-Blöcke
Prot-II-Ida
Blocktherapie
a